Press release
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
March 3, 2023Business Services
Manchester, UK, 3rd March 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver …
Globesity: the silent pandemic of the 21st century. Multidisciplinary and new incisionless endoscopic technique may be an effective solution for adult patients.
March 3, 2023Business Services
London, 03/03/2023- Ahmed is 45 years old and weighed 120 kg. He was always very tired, and would even fall …
Positive Results from POLB 001 LPS Human Challenge Trial
March 2, 2023Business Services
Key Highlights
Menopause Action Plan – How nutritional support can keep female employees at work
March 1, 2023Business Services
Through simple nutrition and lifestyle changes HR managers could enable women to continue to thrive at work and pursue their …
Ten new companies enter BioInnovation Institute’s Venture Lab program
March 1, 2023Business Services
COPENHAGEN, Denmark, March 1, 2023 – BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today …
PureTech to Present at the Barclays Global Healthcare Conference
March 1, 2023Business Services
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment …
Industrywide Survey Reveals Centralising Regulatory is Number One Priority for Medtech
March 1, 2023Business Services
BARCELONA, Spain — 28 Feb. 2023 — New research shows a majority of medtech organizations are taking action to advance …
Ascelia Pharma meets major milestone with patient enrollment completion of Phase 3 Study for Orviglance, novel MRI contrast agent for patients with kidney impairment
February 28, 2023Business Services
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, …
Rare and orphan disease expert Terebellum launches market access guide
February 28, 2023Business Services
Terebellum, subsidiary of global specialty pharmacy and healthcare solutions organisation AscellaHealth, is launching a strategic guide to help manufacturers bring …
Rare disease community call for their unified voice to be heard in the fight for equitable care
February 28, 2023Business Services
Reading, 28th February 2023.
PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)
February 27, 2023Business Services
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded …
Almirall opens the doors of its R&D centre to the biotech ZeClinics
February 27, 2023Business Services
BARCELONA, Spain. February 27th 2023 – Almirall, a global biopharmaceutical company focused on skin health, today announced an agreement with …
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
February 27, 2023Business Services
Hong Kong, Shanghai & Florham Park, NJ — Monday, February 27, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces …
CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System
February 27, 2023Business Services
Cambridge, UK, 27 February 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems …
Five Alarm Bio, Focused on Minimising the Effects of Aging in Humans, Raises Seed Investment
February 27, 2023Business Services
Cambridge, UK, 27 February 2023: Five Alarm Bio (FAB), a drug discovery company focused on novel approaches to anti-aging, announced …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
